Evidence-Based Management of Insomnia
First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)
All adults with chronic insomnia must receive CBT-I as the initial treatment before or alongside any medication, because it provides superior long-term efficacy with sustained benefits lasting up to 2 years after therapy ends, whereas pharmacologic effects disappear when drugs are stopped. 1, 2, 3
Core CBT-I Components
Stimulus control therapy – use the bed only for sleep; leave the bed if unable to fall asleep within ~20 minutes and return only when drowsy 1, 2, 3
Sleep restriction therapy – limit time in bed to actual sleep time + 30 minutes (minimum 5 hours), adjusting weekly based on sleep efficiency (total sleep time ÷ time in bed × 100%) 1, 2, 3
Cognitive restructuring – systematically challenge maladaptive beliefs such as "I cannot function without 8 hours of sleep" or "My insomnia will ruin my health" 1, 2, 3
Relaxation techniques – progressive muscle relaxation, guided imagery, or controlled breathing to reduce physiological arousal 1, 2, 3
Sleep hygiene education – maintain consistent wake time, avoid caffeine ≥6 hours before bed, eliminate screens ≥1 hour before sleep, keep bedroom dark/cool/quiet; insufficient as monotherapy but essential as part of comprehensive CBT-I 1, 2, 3
CBT-I Delivery Options
- Individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books all demonstrate comparable efficacy, making treatment accessible across different settings 1, 2, 3
Pharmacologic Treatment Algorithm (Second-Line, After CBT-I Initiation)
Medications should supplement—not replace—CBT-I, prescribed at the lowest effective dose for the shortest duration (typically ≤4 weeks for acute insomnia per FDA labeling). 1, 2
For Sleep-Onset Insomnia
| Agent | Dose | Key Benefit | Special Considerations |
|---|---|---|---|
| Zolpidem | 10 mg (5 mg if ≥65 years) | Reduces sleep latency by ~25 min [2] | Take ≤30 min before bed with ≥7 hours remaining [2] |
| Zaleplon | 10 mg (5 mg if ≥65 years) | Ultra-short half-life (~1 hour); minimal next-day sedation [2] | Can be taken middle-of-night when ≥4 hours remain [2] |
| Ramelteon | 8 mg | Melatonin-receptor agonist; no abuse potential, no DEA scheduling [2] | Preferred for patients with substance use history [2] |
For Sleep-Maintenance Insomnia
| Agent | Dose | Key Benefit | Special Considerations |
|---|---|---|---|
| Low-dose doxepin | 3–6 mg (≤6 mg if ≥65 years) | Reduces wake after sleep onset by 22–23 min; minimal anticholinergic effects [2,4] | Preferred first-line hypnotic for maintenance problems; no abuse potential [2,4] |
| Suvorexant | 10 mg | Reduces wake after sleep onset by 16–28 min; lower cognitive/psychomotor impairment risk [2] | Orexin-receptor antagonist with different mechanism [2] |
For Combined Sleep-Onset & Maintenance Insomnia
| Agent | Dose | Key Benefit | Special Considerations |
|---|---|---|---|
| Eszopiclone | 2–3 mg (1 mg if ≥65 years or hepatic impairment) | Increases total sleep time by 28–57 min; moderate-to-large improvement in subjective quality [2] | FDA-approved for longer-term use compared to other BzRAs [2] |
| Daridorexant | Per FDA dosing | Similar efficacy to other orexin antagonists [2] | May be continued up to 3 months or longer in selected cases [2] |
Medications Explicitly NOT Recommended
Trazodone
- The American Academy of Sleep Medicine issues a recommendation AGAINST trazodone for insomnia because it reduces sleep latency by only ~10 minutes with no improvement in subjective sleep quality, while adverse events occur in ~75% of older adults 1, 2, 3
Over-the-Counter Antihistamines
- Diphenhydramine and doxylamine are NOT recommended due to lack of efficacy data, strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation, delirium), and tolerance development within 3–4 days 1, 2, 3
Antipsychotics
- Quetiapine and olanzapine must NOT be used for insomnia; evidence of benefit is weak and they carry significant risks including weight gain, metabolic syndrome, extrapyramidal symptoms, and increased mortality in elderly patients with dementia 1, 2, 3
Traditional Benzodiazepines
- Lorazepam, clonazepam, and diazepam should be avoided due to long half-lives causing accumulation, daytime sedation, higher fall/cognitive-impairment risk, and associations with dementia and fractures 1, 2
Melatonin Supplements & Herbal Products
- Melatonin supplements produce only ~9 minutes reduction in sleep latency; insufficient evidence for chronic insomnia 1, 2
- Valerian, L-tryptophan, and other herbal supplements lack adequate evidence to support use for primary insomnia 1, 2
Special Population Considerations
Older Adults (≥65 Years)
Reduce all hypnotic doses: zolpidem ≤5 mg, eszopiclone ≤2 mg, zaleplon ≤5 mg, doxepin ≤6 mg 2, 4
Low-dose doxepin 3 mg and ramelteon 8 mg are the safest first-line options because they carry minimal fall and cognitive-impairment risk 2, 4
Avoid anticholinergic agents (OTC antihistamines, high-dose tricyclics) due to risk of confusion, urinary retention, falls, and delirium 2, 4
Patients with Comorbid Depression or Anxiety
- Sedating antidepressants (mirtazapine 7.5–30 mg, low-dose doxepin) may be considered third-line after benzodiazepine-receptor agonists have failed, especially when mood disorders are present 1, 2
Safety Monitoring & Duration
Reassessment Protocol
Evaluate after 1–2 weeks: sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects (somnolence, cognitive impairment, complex sleep behaviors) 1, 2
Document continued need after 4 weeks; if effective, plan gradual taper while maintaining CBT-I 1, 2
Critical Safety Warnings
All benzodiazepine-receptor agonists carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating); discontinue immediately if these occur 1, 2
Combining multiple sedating agents markedly increases risk of respiratory depression, cognitive impairment, falls, and fractures 1, 2
Observational data link hypnotic use to increased dementia, fractures, and major injuries, although causality is unproven 1, 2
Persistent insomnia beyond 7–10 days despite treatment warrants evaluation for underlying sleep disorders (sleep apnea, restless-legs syndrome, circadian-rhythm disorders) 1, 2
Common Pitfalls to Avoid
Starting pharmacotherapy without first implementing CBT-I violates strong guideline recommendations and yields less durable benefit 1, 2, 3
Using adult dosing in older adults; age-adjusted dosing is mandatory to reduce fall risk 2, 4
Prescribing trazodone, OTC antihistamines, or antipsychotics for primary insomnia; these lack efficacy and carry significant safety concerns 1, 2, 3
Continuing hypnotics beyond 4 weeks without periodic reassessment; FDA labeling limits short-term use 1, 2
Failing to match medication to insomnia phenotype: use zaleplon/ramelteon/zolpidem for sleep-onset difficulty, low-dose doxepin/suvorexant for maintenance difficulty, eszopiclone/daridorexant for combined symptoms 2